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Aims Recent technological advances enable diagnosing of obstructive coronary artery disease (CAD) from heart sound
analysis with a high negative predictive value. However, the prognostic impact of this approach remains unknown.
To investigate the prognostic value of heart sound analysis as two scores, the Acoustic-score and the CAD-score,




Consecutive patients with angina symptoms referred for coronary computed tomography angiography (CTA) were
enrolled. The Acoustic-score was developed from eight acoustic CAD-related features. This score was combined
with risk factors to generate the CAD-score. A cut-off score >20 was pre-specified for both scores to indicate dis-
ease. If coronary CTA raised suspicion of obstructive CAD, patients were referred to invasive angiography and
revascularized when indicated. Of 1675 enrolled patients, 1464 (87.4%) were included in this substudy. The com-
bined primary endpoint was all-cause mortality and myocardial infarction (n = 26). Follow-up was 3.1 (2.7–3.4)
years. Of patients with primary endpoints, the Acoustic-score was >20 in 25 (96%); the CAD-score was >20 in 22
(85%). In an unadjusted Cox analysis of the primary endpoints, the hazard ratio for scores >20 under current
standard clinical care was 12.6 (1.7–93.2) for the Acoustic-score and 5.4 (1.9–15.7) for the CAD-score. The CAD-
score contained prognostic information even after adjusting for lipid-lowering therapy initiation, stenosis at CTA,
and early revascularization.
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Introduction
Pre-test probability stratification of patients with suspected obstruct-
ive coronary artery disease (CAD) has been suboptimal for many
years. Hence, most diagnostic tests to rule out CAD show normal
conditions.1–3
Acoustic devices measuring the heart sound originating from tur-
bulent blood flow in the coronary circulation and altered myocardial
relaxation have therefore been developed. These devices have been
shown to be effective in ruling out CAD, and to outperform other
methods by being faster, risk-free and more cost-effective.4
The diagnostic performance of two acoustic algorithms was re-
cently tested in two large studies of patients presenting with symp-
toms suggestive of obstructive CAD.5–7 The studies demonstrated
that these algorithms were positively correlated with the extent of
CAD in terms of coronary artery calcium score, maximal diameter
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stenosis, and number of vessels with disease. The studies demon-
strated high sensitivities of 78–81%, moderate specificities of 35–53%
but a high negative predictive value of 91–96%. It is therefore possible
that these algorithms may serve as rule-out tests in patients with sus-
pected stable CAD.
However, no study has investigated whether heart sound carries
any prognostic information. The acoustic features included in these
acoustic algorithms have been linked to coronary stenosis degree,
coronary flow volume and velocity, vascular stiffness, left ventricular
diastolic, and systolic dysfunction—all markers which are predictive
of a poor prognosis.6,8–14
The aim of this study was to investigate the prognostic value of
pre-specified heart sound analysis (Acoustic-score) and an acoustic
pre-test probability score (CAD-score) in patients with symptoms
suggestive of CAD referred for coronary computed tomography
angiography (CTA) and subsequently treated according to standard
of care.
Materials and methods
Study design and population
The present predefined substudy used patients from the Danish study of
the Non-Invasive Testing in Coronary Artery Disease (Dan-NICAD) trial
1.15,16 Patients referred to coronary CTA due to symptoms suggestive of
obstructive CAD were enrolled consecutively between September 2014
and March 2016. Patients were referred to coronary CTA after evalu-
ation by a cardiologist in an outpatient cardiology unit. Decisions regard-
ing referral to coronary CTA were based on patients’ history, symptoms,
risk profile, and echocardiographic findings according to national and
European Society of Cardiology guidelines. Exclusion criteria were: (i) age
<40; (ii) previous known CAD; (iii) estimated glomerular filtration
<40 mL/min; (iv) pregnancy; and (v) contra-indication for iodine-contain-
ing contrast medium, magnetic resonance imaging, or adenosine (severe
asthma, advanced atrioventricular block, or critical aorta stenosis). All
patients signed a written informed consent form. The Central Denmark
Region Committees on Health Research Ethics, The Danish Medicines
Agency, and The Danish Data Protection Agency approved the study,
including the present 10-year follow-up substudy.
All included patients underwent a systematic interview to assess risk
factors and symptoms and underwent coronary CTA. During their visit
for coronary CTA, an examination with the acoustic microphone,
CADScorVR System (Acarix A/S, Denmark) was performed. Patients with
suspicion of a coronary stenosis at coronary CTA all underwent invasive
coronary angiography (ICA) with fractional flow reserve (ICA-FFR) meas-
urement approximately 4 weeks after the coronary CTA. Patients with-
out stenosis at coronary CTA did not undergo further testing. Follow-up
data were obtained from electronic patient records and Danish national
health registries (Figure 1).
The study design, imaging protocols, and analysis strategy have been
published.16
CAD-score
Heart sound recordings were obtained with the CADScorVR System which
is a small transportable electronic stethoscope device consisting of
microphones and a micro-computer with a display. The microphone is
mounted at the 4th intercostal space just to the left of the sternum with a
dedicated adhesive patch during 5 min of rest. During the 3-min record-
ing, the patient is asked to hold his/her breath for a period of 8 s, four
times.
Figure 1 Flow chart of patients in the study. CAD, coronary artery disease; CTA, computed tomography angiography; FFR, fractional flow reserve;
ICA, invasive coronary angiography.



































..Recordings were conducted in an undisturbed room. The
CADScorVR System analyses the quality of the recording and in case of
poor quality, the device requests a second recording.
The CADScorVR System algorithm Version 3 (V3) algorithm was utilized
to calculate the Acoustic-score per se based on post-processing of audio
recordings of the heart sound. In total, eight acoustic features related to
turbulence murmurs and other heart sound characteristics in CAD were
included in the Acoustic-score (Figure 2). The CAD-score V3 was gener-
ated by combining the Acoustic-score with the risk factors; gender, age,
and hypertension (Figure 2).
In this paper, we present data from the Acoustic-score version 3 with-
out risk factor modification and the CAD-score version 3. Both an




All patients in the Dan-NICAD trial underwent coronary CTA scans on a
320-slice volume CT scanner (Aquillion One, Toshiba Medical Systems,
Japan) according to clinical guidelines.
CT imaging analysis included an Agatston calcium score and evaluation
of CAD including luminal diameter stenosis estimation in each segment
of the coronary tree using an 18-segment model. Coronary lesions were
evaluated blinded to patient history. Stenosis severity was classified in all
segments with a reference vessel diameter >2 mm. Severe stenosis was
defined as 50–100% diameter reduction (70% to 100% area reduction).
Segments with suspected severe stenosis and non-evaluable segments
with a reference vessel diameter >2 mm were defined as having obstruct-
ive CAD by coronary CTA and referred to ICA.
Invasive coronary angiography
Patients with suspected obstructive CAD at the coronary CTA were
referred to ICA. ICA-FFR was measured in lesions with a visually esti-
mated 30–90% diameter stenosis located in vessels with a reference
diameter >2.0 mm using a clinical ICA-FFR system (Aeris, St. Jude
Medical, Minnetonka, MN, USA). Haemodynamically obstructive CAD
was identified in a blinded core lab as: (i) ICA-FFR value <0.80, (ii) luminal
diameter stenosis reduction >90%, or (iii) luminal diameter stenosis re-
duction >_50% if ICA-FFR was indicated but not performed for technical,
anatomical, or other reasons.
Figure 2 Depiction of the acoustic diagnostic method. (A) Coronary artery disease-score is calculated based on a 3-min recording session from
the IC4-L region. Three patient risk factors are combined with acoustic derived data to generate a coronary artery disease-score. A score <_20 is con-
sidered low risk and used to substantiate rule-out for coronary artery disease. (B) The acoustic data are derived from both the systolic and diastolic
periods. The acoustic recording is segmented into discrete heart beats and aligned according to S2. Heart beats containing excess noise are filtered
out, and the Acoustic-score is calculated. Several acoustic features having different, distinct coronary and myocardial origins are combined into the
Acoustic-score.






























































































Revascularizations were performed according to standard clinical
practice after the ICA. Decisions were made blinded for CAD-score and
other diagnostic test results.
Follow-up
Clinical endpoint data were extracted from patient records and Danish
national health databases. Using the Civil Personal Registration number
assigned to each Danish citizen at birth, we obtained information regard-
ing mortality, diagnosed diseases, in-hospital procedures, and medical
treatment. The CAD-score remained blinded to clinicians during follow-
up. End of follow-up was set to 30 June 2018.
Information on mortality, myocardial infarction, and revascularization
with either percutaneous coronary intervention (PCI) or coronary artery
bypass graft (CABG) was obtained from the Western Denmark Heart
Registry, the Danish National Patient Registry, and/or Danish Civil
Personal Register. Data on Medical treatment and compliance were
extracted from reimbursed medical prescriptions at Danish pharmacies
through the Danish National Health Service Prescription Database.
Changes in lipid lowering therapy after primary cardiac evaluation were
defined as continued, discontinued, initiated, or no therapy according to
both pre- and post-test-issued prescriptions within a window of 180 days
before and 120 days after the examination.
Statistical analysis
The primary study endpoint was defined as a composite endpoint of all-
cause mortality and myocardial infarction blinded for the first 120 days
after coronary CTA. Secondary endpoints were early and late revascula-
rization with a cut-off of 120 days with death as competing risk, and any
coronary events blinded for the first 120 days after coronary CTA (all-
cause mortality, myocardial infarction, and late revascularization).
Patients who were revascularized early in relation to the baseline cardiac
diagnostic evaluation were not excluded from the follow-up.
The primary aim was to compare scores with a cut-off value of 20,
however for the CAD-score, we also considered the three groups:
CAD-scores <_20 (reference), CAD-scores 21–29, and CAD-scores >_30,
as well as an increment of the CAD-score of 10 units.
Time-to-event analysis was performed with univariate and multivariate
Cox regression of the cause-specific hazard ratios (HRs). Cumulative inci-
dence functions for each endpoint were generated to illustrate the risk
over time. For Cox multiple regression analysis, we pre-specified models
which included an updated Diamond–Forrester score, coronary disease
severity at coronary CTA with stratification for change in medication, and
revascularization as part of the Dan-NICAD trial’s cardiac evaluation.
However, post hoc we chose to develop several models with the endpoint
of any cardiac event due to the low number of events. Cox multiple re-
gression analysis was pre-specified to be blinded for the period of the first
120 days from baseline to enable adjustment of change in medication and
revascularization as part of the baseline cardiac evaluation. In the blinded
period, two patients died. They were the only ones excluded in the Cox
multiple regression analysis.
For all statistical analyses, 95% confidence intervals (CIs) were
reported when appropriate. The statistical analyses were performed
using STATA-15.
Results
Of 1675 patients enrolled in the Dan-NICAD trial, 1464 (87.4%)
were included in this study. In total, 211 (12.6%) were excluded due
to missing CAD-score V3 (characteristics specified in Supplementary
material online, Table S1). Baseline characteristics are listed in Table 1.
The median Acoustic-score was 24 (14–29). The Acoustic-score
correlated vaguely with age, Spearman’s rho 0.11 (P < 0.001), and
was higher in males than in females, 27 (21–32) vs. 21 (16–25)
(P < 0.001). A total of 488 (33%) patients had an Acoustic-score <_20,
indicating low risk.
The median CAD-score was 20 (10–31). The CAD-score was
positively correlated with age, Spearman’s rho 0.50 (P < 0.001), and
was higher in males than in females: 28 (15–31) vs. 15 (7–24)
(P < 0.001), respectively. A total of 723 (49%) patients had a CAD-
score <_20, indicating low risk. The CAD-score was positively corre-
lated with the Acoustic-score, Spearman’s rho 0.54 (P < 0.001).
Furthermore, 2  2 tables for the scores are available in
Supplementary material online, Table S2).
Diagnostic imaging characteristics of the baseline cardiac evalu-
ation including echo, coronary CTA, ICA-FFR measurements, and
revascularization related to the baseline cardiac evaluation, which
were part of the Dan-NICAD trial, are summarized in Table 2. The
median inter-test interval between coronary CTA and ICA was 30
days (10th and 90th percentiles: 14 and 50 days).
Treatments initiated at baseline
Lipid-lowering therapy was initiated based on baseline cardiac evalu-
ation in 103 (14.3%) patients with a CAD-score <_20 and in 184
(24.8%) with a CAD-score >20 (Supplementary material online,
Figure S1). However, at baseline, plasma cholesterol levels were also
higher in patients initiating lipid lowering therapy than in others,
5.8± 1.1 vs. 5.3± 1.0 mmol/L, P < 0.001.
In total, 140 patients were diagnosed with haemodynamically ob-
structive CAD at ICA based on the baseline cardiac evaluation; and
112 patients were subsequently early revascularized according to
standard clinical practice, 62 with PCI and 50 with CABG (secondary
endpoint, Tables 3 and 4). CAD-scores were significantly higher in
the 112 revascularized patients than in the 1352 patients without
revascularization related to the primary cardiac evaluation, 31 (21–
40) vs. 19 (10–30) (P < 0.001), respectively. A detailed description of
clinical information and imaging characteristics of the 26 patients who
were revascularized and had a CAD-score <_20 is presented in
Supplementary material online, Table S3.
Prognostic value of heart sound analysis
The combined primary endpoint occurred in 26 patients; 16 patients
died and 10 patients had a myocardial infarction within a median fol-
low-up time of 3.1 (2.7–3.4) years. In total, nine patients had late
revascularization (>120 days after inclusion) (Supplementary material
online, Table S4).
The isolated Acoustic-score without inclusion of risk factors was
>20 in 25 out of 26 (96%) patients with the primary endpoint, mor-
tality and myocardial infarction (Table 3). The unadjusted HR was
12.6 (1.7–93.2), P < 0.05. The HR of the Acoustic-score did not in-
crease for Acoustics-scores >_30 compared with scores in the 21–29
range. Acoustic-score >20 had an HR for early revascularization
within 120 days of 2.3 (1.4–3.6) but did not predict late revasculariza-
tion (Figure 3, Supplementary material online, Figure S2).
The CAD-score was >20 in 22 of 26 (85%) patients with the com-
bined primary endpoint—in 12 of 16 (75%) of patients who died, and
in all 10 patients who had myocardial infarction. In addition, CAD-






























..score was >20 in all patients who underwent late revascularization
(>120 days after inclusion) (Table 4).
In an unadjusted Cox regression analysis of the combined pri-
mary endpoint, CAD-scores >20 had an HR of 5.4 (1.9–15.7),
P < 0.01. The HR increased significantly with higher CAD-score;
with CAD-scores <_20 as reference, CAD-scores 21–29 and
CAD-scores >_30 had a HR of 3.0 (0.9–10.8), P = 0.09, and 7.7
(2.6–22.9), P < 0.001, respectively (Figure 4 and Supplementary ma-
terial online, Figure S2).
It was not possible to calculate the HR for late revascularization as
there were no events in patients with CAD-scores <_20. However,
the log-rank test for late revascularization was significant, P < 0.001
(Figure 4).
In Cox regression analysis of any cardiac events after 120 days
(secondary endpoint: death, myocardial infarction, or revasculariza-
tion >120 days), a CAD-score increment of 10 units had an HR of 1.8
(1.3–2.5) P < 0.01, which was not influenced by adjustment for sex
and age. In contrast to the updated Diamond–Forrester score, the
CAD-score remained significant after including the updated
Diamond–Forrester score in the model. Finally, the CAD-score
remained significantly associated with events after adjusting for
(i) coronary stenosis at coronary CTA and (ii) lipid lowering therapy
initiation and revascularization (Table 5).
In a stratified analysis of patients not revascularized as part of the
baseline cardiac evaluation (n = 1352), a CAD-score >20 had an HR
of 3.9 (1.1–13.9), P < 0.05, and a CAD-score increase of 10 units had
an HR of 1.5 (1.0–2.3), P = 0.05, for events after 120 days (dead, myo-
cardial infarction or revascularization >120 days). Similarly, in patients
(n = 112) who were revascularized, all patients who died or had myo-
cardial infarction or revascularization >120 days had a CAD-score
>20, and a CAD-score increment of 10 units had an HR of 1.5 (0.8–
2.6), P = 0.17, for events after 120 days.
....................................................................................................................................................................................................................
Table 1 Baseline characteristic of included patient demographics (N 5 1464)
Total CAD-score 20 CAD-score >20
Number of patients 1464 723 (49.3%) 741 (50.7%)
Characteristic
Race, Caucasian 1454 (99.3%) 717 (99.2%) 737 (99.5%)
Sex, male 716 (48.9%) 257 (35.6%) 459 (62.9%)
Age (years) 57.1 ± 8.7 53.3 ± 8.0 60.8 ± 7.8
Body mass index (kg/m2) 26.6 ± 4.1 26.3 ± 4.1 27.0 ± 4.1
Abdominal circumference (cm) 93.0 ± 12.6 90.6 ± 12.3 95.3 ± 12.5
Blood pressure
Systolic 138 ± 19 129 ± 14 148 ± 18
Diastolic 83 ± 11 79 ± 10 86 ± 11
Heart ratea 65 ± 11 65 ± 11 66 ± 11
Smoking
Never 697 (47.6%) 343 (47.4%) 354 (47.8%)
Former 536 (36.6%) 245 (33.9%) 291 (39.3%)
Active 231 (15.8%) 135 (18.7%) 96 (13.0%)
Diabetes 79 (5.4%) 24 (3.3%) 55 (7.4%)
Symptoms
Typical chest pain 407 (27.8%) 203 (28.1%) 204 (27.5%)
Atypical chest pain 493 (33.7%) 259 (35.8%) 234 (31.6%)
Non-specific 564 (38.5%) 261 (36.1%) 303 (40.9%)
Updated Diamond Forrester score 39% (20–54%) 28% (16–45%) 42% (29–59%)
Low risk (<15%) 210 (14.3%) 168 (23.2%) 42 (5.7%)
Moderate risk (>_15% to 85%) 1220 (83.3%) 555 (76.8%) 665 (89.7%)
High risk (>_85%) 34 (2.3%) 0 (0.0%) 34 (4.6%)
Medication
Hypertension 491 (33.8%) 86 (12.1%) 405 (45.9%)
Mean number of antihypertensives 1.9 ± 1.0 1.9 ± 0.9 1.8 ± 1.0
Hypercholesterolaemia 398 (27.2%) 145 (20.0%) 253 (34.1%)
Biochemistryb
Cholesterol (total, mmol/L) 5.4 ± 1.1 5.4 ± 1.1 5.3 ± 1.1
HbA1c (mmol/mol) 37.7 ± 7.2 37.1 ± 7.0 38.3 ± 7.2
Creatinine (mmol/L) 75.4 ± 14.6 72.4 ± 12.8 78.3 ± 15.6
Values are n (%) or mean ±SD or median (IQR).
aMean heart rate at the time of CAD-score measurement was: 54 ± 7 b.p.m. and at the time of CTA: 56 ± 7 b.p.m.
bData available in: cholesterol 94%, glucose fasting 8%, HbA1c 78%, and creatinine 99% of the cohort.













In a ‘worst case scenario’ simulation, an event was assigned to all
patients with early revascularization as part of the primary baseline
cardiac evaluation and with a false negative CAD-score <_20 (n = 26).
In this scenario, CAD-scores >20 had similarly 5-year events rates,
for any mortality, myocardial infarction, late revascularization not
part of the primary baseline evaluation, and early revascularization as
....................................................................................................................................................................................................................
Table 2 Imaging study characteristics from the baseline cardiac evaluation which were protocolized in the Dan-
NICAD trial
Total CAD-score 20 CAD-score >20
Number of patients 1464 723 (49.3%) 741 (50.7%)
Echo (n = 1438)
Left ventricular ejection fraction 59.9% ± 3.4 60.0% ± 2.6 59.5% ± 4.0
Cardiac valve disease, any 69 (4.7%) 23 (3.2%) 46 (6.2%)
Coronary artery calcium score (n = 1459)
Median 0 (0–81) 0 (0–13) 25 (0–192)
Coronary artery calcium score (CACS) groups
None (CACS = 0) 747 (51.2%) 472 (65.7%) 275 (37.2%)
Low/moderate (CACS: 1–399) 564 (38.7%) 219 (30.5%) 345 (46.6%)
High (CACS >_400) 148 (10.1%) 28 (3.9%) 120 (16.2%)
Cardiac computed tomography angiography (n = 1457)
Coronary artery disease severity
Non (stenosis 0% and CACS = 0) 696 (47.8%) 449 (62.5%) 247 (33.5%)
Mild (stenosis 0–30%) 306 (21.0%) 126 (17.5%) 180 (24.4%)
Moderate (stenosis 30–50%) 111 (7.6%) 51 (7.1%) 60 (8.1%)
Severe (stenosis 50–100%) 344 (23.6%) 93 (12.9%) 251 (34.0%)
Radiation dose per coronary CTA (mSv) 2.7 ± 1.7 2.4 ± 1.5 2.9 ± 1.8
Invasive coronary angiography with fractional flow reserve (n = 321)a
Coronary artery disease severity
Obstructive stenosis 140 (9.7%) 27 (3.8%) 113 (15.6%)
Number of coronary vessels with severe stenosis
One-vessel disease 85 (5.9%) 16 (2.3%) 69 (9.5%)
Two-vessel disease 37 (2.6%) 8 (1.1%) 29 (4.0%)
Three-vessel disease or left main disease 18 (1.3%) 3 (0.4%) 15 (2.1%)
Values are n (%) or mean ± SD or median (IQR).
CACS, Coronary artery calcium score.
aICA were only indicated in patient with severe stenosis at coronary CTA.
....................................................................................................................................................................................................................
Table 3 Tables of events during follow-up according to the Acoustic-score
Total Acoustic-score 20 Acoustic-score >20
Number of patients 1464 448 (33.3%) 667 (66.7%)
Primary endpoint
Mortality and myocardial infarction 26 (1.8%) 1 (0.2%) 25 (2.6%)
Secondary endpoints
Mortality, all-cause 16 (1.1%) 1 (0.2%) 15 (1.5%)
Myocardial infarction 10 (0.7%) 0 (0.0%) 10 (1.0%)
Procedure related/spontaneous 2/8 0/0 2/8
Early/late (cut-off 120 days) 7/3 0/0 7/3
Early revascularization (<_120 days) 115 (7.9%) 21 (4.3%) 94 (9.6%)
Part of the primary Dan-NICAD evaluation 112 21 91
Acute 3 0 3
Late revascularization (>120 days) 9 (0.6%) 3 (0.6%) 6 (0.6%)
Values are n (%).
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Table 4 Tables of events during follow-up according to the CAD-score
Total CAD-score 20 CAD-score >20
Number of patients 1464 723 (49.3%) 741 (50.7%)
Primary endpoint
Mortality and myocardial infarction 26 (1.8%) 4 (0.6%) 22 (3.0%)
Secondary endpoints
Mortality, all-cause 16 (1.1%) 4 (0.6%) 12 (1.6%)
Myocardial infarction 10 (0.7%) 0 (0.0%) 10 (1.4%)
Procedure related/spontaneous 2/8 0/0 2/8
Early/late (cut-off 120 days) 7/3 0/0 7/3
Early revascularization (<_120 days) 115 (7.9%) 26 (3.6%) 89 (12.0%)
Part of the primary Dan-NICAD evaluation 112 26 86
Acute 3 0 3
Late revascularization (>120 days) 9 (0.6%) 0 (0.0%) 9 (1.2%)
Values are n (%).
Figure 3 Primary and secondary endpoints according to Acoustic-score with a pre-specified cut-off >20.






































.part of the primary cardiac evaluation with CAD-score <_20
(Supplementary material online, Figure S3).
Discussion
In this study, we present prognostic data showing that an Acoustic-
score derived from heart sound has prognostic impact in patients
with symptoms suggestive of CAD referred to cardiac CT. This
Acoustic-score combined with risk factors, the CAD-score, demon-
strated an HR >5 for the primary endpoint, a composite of myocar-
dial infarction and all-cause mortality, at a pre-specified binary
cut-point of CAD-score of 20. The prognostic value rose with higher
CAD-score, HR >7.5 for CAD-score >_30 compared with <_20. In
addition, the CAD-core remained a prognostic predictor after adjust-
ing for the updated Diamond–Forrester score and coronary stenosis
at coronary CTA.
Acoustic detection of CAD
Acoustic detection of turbulent blood flow in coronary stenosis was
first described in 1967 as a high-frequency diastolic murmur.17 Since
then, heart sound analysis has allowed differentiation between no,
early, and advanced stages of CAD, as illustrated by diastolic fre-
quency spectrum plots.5,18 Technological improvements in heart
sound recording, segmentation, and analysis have enabled the devel-
opment of an acoustic device for ruling out obstructive CAD.
Two large studies have tested the diagnostic accuracy of these
acoustic rule-out devices in stable CAD. The CADence device was
evaluated in the TURBULENCE study, a 21-sites multicentre study in
the USA.7 The CADence device uses multiple recording positions
and is handheld during the recording. Patients (n = 785) referred for
nuclear stress testing due to chest pain symptoms and two or more
CAD risk factors were included. Nuclear stress testing was followed
by either coronary CTA or ICA as a reference standard with >_70%
diameter stenosis indicating obstructive CAD. Disease prevalence
was 15%, and the CADence device had a sensitivity of 78%, a specifi-
city of 35%, and a positive and negative predictive value of 17% and
91%, respectively.
In the Dan-NICAD trial, the CADScorVR System was tested in
1,675 patients with predominately intermediate risk of CAD who
had been referred for coronary CTA.6 Patients were referred from
five Danish hospitals, and coronary CTA was performed at two high-
Figure 4 Primary and secondary endpoints according to coronary artery disease-score with a pre-specified cut-off >20.
























































..volume centres. Patients with a coronary stenosis at coronary CTA
underwent ICA with FFR, and haemodynamically obstructive CAD
was defined as ICA-FFR <0.80. In Denmark, coronary CTA is the
first-line test for ruling out CAD in de novo patients, which results in a
low disease prevalence of 10% in the Dan-NICAD trial compared
with 15% in TURBULENCE. The CADScorVR System had sensitivity of
81%, a specificity of 53%, and a positive and negative predictive value
of 16% and 96%, respectively; hence, similar sensitivities and positive
predictive values but higher specificities and negative predictive val-
ues than the TURBULENCE study.
Prognostic value of acoustic analysis of
heart sound
The present study is the first study to evaluate the prognostic value
of an acoustic analysis of heart sounds. An isolated Acoustic-score of
eight heart sound features related to CAD predicted 25 out of 26
myocardial infarctions or deaths. Combining the Acoustic-score with
risk factors to obtain the CAD-score increased the proportion of
patients with a score <_20, and thus a low probability of CAD, from
33% to nearly 50%. Nonetheless, the CAD-score remains highly
predictive for both deaths, myocardial infarctions, and late
revascularization.
The prognostic value of the CAD-score remained significant after
adjustment for coronary stenosis, which is a very strong prognostic
predictor in stable CAD. This is due to specific acoustic features
related to, e.g. high-risk plaque characteristic. However, further re-
search is needed regarding the origin of these acoustic features and
their correlation with specific pathologies.
The Dan-NICAD trial was designed to evaluate the diagnostic ac-
curacy of the CAD-score with a reference of haemodynamic coron-
ary stenosis at ICA.6 Decisions regarding medical treatment and
revascularization were based on standard clinical care; thus, no
decision was taken based on the CAD-score. In patients with a CAD-
score <_20, lipid lowering therapy was initiated in 103 (14.3%) and
26 (3.6%) were revascularized. These patients had a therapy that
might have altered their prognosis and affected the outcome of the
present study. We performed multiple regression and stratified anal-
yses to adjust for this confounder, and the conclusion on the progno-
sis was unaffected.
Finally, we performed a ‘worst case scenario’ presuming the situ-
ation that all early revascularized patients with CAD-scores <_20 had
an event of death, myocardial infarction, or late revascularization—as
mimic the most severe consequence if we had not offered early
revascularization to these patients due to rule-out based on CAD-
score. In this scenario, a CAD-score >20 was no longer a predictor
of prognosis. Contradict, 723 patients with a CAD-score <_20 would
not have need coronary CTA for ruling out obstructive CAD.
Hence, a reduction in contrast agent and iodinated radiation of
>1700 mSv (723 patients with an averaged radiation dose of 2.4 mSv
per coronary CTA) could be achieved in this study despite we used
newer generations of CT scanners.
Limitations
This cohort comprised almost exclusively Caucasians with low to
intermedia pre-test probability of CAD and none had previously
documented CAD. Patients were referred to coronary CTA as the
first-line diagnostic test according to Danish standard of care. This ap-
proach might have introduced referral bias base on pre-test probabil-
ity and due to the limitations of coronary CTA, e.g. irregular heart
rate and severe obesity.
The development of CAD-score V3 required splitting the cohort
into a consecutive training (n = 593) and a blinded validation
(n = 1082) cohort, which might have over-fitted the results in the
....................................................................................................................................................................................................................




CAD-score per 10 unit 1.8 (1.3–2.5) P < 0.01 1.8 (1.1–2.8) P < 0.05
Sex, male 2.1 (0.9–5.0) P = 0.08 1.1 (0.4–3.0) P = 0.84
Age per 10 years 1.5 (0.9–2.3) P = 0.11 1.0 (0.6–1.7) P = 0.95
Model B
CAD-score per 10 unit 1.8 (1.3–2.5) P < 0.01 1.7 (1.2–2.4) P < 0.01
Diamond–Forrester score 10 unit 1.2 (1.0–1.4) P < 0.05 1.1 (0.9–1.3) P = 0.52
Model C
CAD-score per 10 unit 1.8 (1.3–2.5) P < 0.01 1.6 (1.1–2.4) P < 0.05
Diamond–Forrester score 10 unit 1.2 (1.0–1.4) P < 0.05 1.0 (0.8–1.2) P = 0.88
Severe stenosis at coronary CTA 6.1 (2.6–14.3) P < 0.001 4.2 (1.7–10.4) P < 0.01
Model D
CAD-score per 10 unit 1.8 (1.3–2.5) P < 0.01 1.5 (1.1–2.1) P < 0.05
Lipid lowering therapy initiated 4.1 (1.9–9.2) P < 0.01 2.0 (0.8–4.9) P = 0.13
Revascularization at baseline 8.9 (3.9–20.0) P < 0.001 4.6 (1.8–11.6) P < 0.01
CAD-score and updated Diamond–Forrester scores are analysed as a continuous variable per 10 units.
Values are hazard ratios (CI 95%).
















































































total cohort analysis. However, diagnostic accuracy in the validation
vs. training cohort indicated no over-fitting.6
The CAD-score does not distinguish between diastolic murmurs
origination. Hence, diastolic valve disease may decrease CAD-score
specificity as it increases the false positive rate but sensitivity remains
high.19
Finally, this study is limited by the low event rates reflecting an
overall favourable prognosis of patients with stable CAD. Hence, the
results of this study are promising but should be interpreted with
caution and final conclusions regarding the safety of acoustic rule-out
strategies should await results of randomized controlled strategy
trials.
Conclusion
The Acoustic-score derived from heart sound seems to give prog-
nostic information about mortality, myocardial infarction, and late
revascularization in patients with symptoms suggestive of CAD which
is treated according to standard of care. Diagnostic algorithms of this
Acoustic-score combined with risk factors developed for ruling out
CAD, the CAD-score, risk-stratified patients even further. These
findings are useful as new automated acoustic diagnostic devices have
emerged for ruling out obstructive CAD.
Supplementary material
Supplementary material is available at European Heart Journal is avail-
able at online.
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